CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma
CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma
复制标题
DOI：
10.1354/vp.42-4-468
复制
发表时间：
2005-07-01
影响因子：
2.4
通讯作者：
Modiano, JF
中科院分区：
文献类型：
--
作者：
Jubala, CM;Wojcieszyn, JW;Modiano, JF
我们研究了CD 20在正常犬外周血单核细胞，正常犬脾，和犬非霍奇金淋巴瘤（NHL）的表达，以确定使用这种抗原作为诊断援助的可行性，并作为一个可能的治疗目标。针对人CD 20的C-末端（胞质内）表位产生的抗体识别正常和恶性犬淋巴细胞中32-36 kd的蛋白质。这种抗体显示出限制性的膜结合在外周血中的淋巴细胞的一个子集中，在B细胞区域从一个正常的犬脾和淋巴结，并在恶性细胞从19只狗与B细胞NHL，但不是从15只狗与T细胞NHL。这些样本中的CD 20反应性模式与使用识别犬CD 79 a的抗体观察到的模式重叠。因此，这种抗CD 20抗体适合作为犬NHL表型的辅助。相比之下，正常犬B细胞不被针对人CD 20的细胞外结构域的28种抗体（包括嵌合小鼠-人抗体利妥昔单抗）中的任一种或针对小鼠CD 20的细胞外结构域的12种抗体中的任一种识别。因此，使用CD 20作为治疗靶点将需要产生针对犬CD 20胞外结构域的特异性抗体。
We examined the expression of CD20 in normal canine peripheral blood mononuclear cells, normal canine spleen, and canine non-Hodgkin lymphoma (NHL) to determine the feasibility of using this antigen as a diagnostic aid and as a possible target for therapy. An antibody generated against a C-terminal (intracytoplasmic) epitope of human CD20 recognized proteins of 32-36 kd in normal and malignant canine lymphocytes. This antibody showed restricted membrane binding in a subset of lymphocytes in peripheral blood, in the B-cell regions from a normal canine spleen and lymph node, and in malignant cells from 19 dogs with B-cell NHL, but not from 15 dogs with T-cell NHL. The patterns of CD20 reactivity in these samples overlapped those seen using an antibody that recognizes canine CD79a. This anti-CD20 antibody is therefore suitable as an aid to phenotype canine NHL. In contrast, normal canine B cells were not recognized by any of 28 antibodies directed against the extracellular domains of human CD20 (including the chimeric mouse-human antibody Rituximab) or by any of 12 antibodies directed against the extracellular domains of mouse CD20. Thus, the use of CD20 as a therapeutic target will require the generation of specific antibodies against the extracellular domains of canine CD20.